Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy

Objective:The aim of our study is to describe the progression-free survival (PFS) in patients with clinical stage (CS) II and III NSGCT with an RM after primary or secondary CT with negative serum markers (NSM).A residual mass (RM) in non-seminomatous germ cell tumors (NSGCT) after chemotherapy (CT) is defined as a mass >1 cm in greatest diameter.The preferred treatment for RM is retroperitoneal lymph node dissection (RPLND), with a cure rate greater than 80%.Methods: We identified 60 patients with NSGCT, RM, and NSM between 2007 and 2020.Data regarding clinical and oncological outcomes as well as pathological information were obtained in a retrospective fashion from our electronic database.Results: A total of 60 patients were included.50% of cases were CS II, and 50% CS III.About 90% of the patients had undergone RPLND.Teratoma was found in 73.6% of these patients.PFS and OS were better in CS II patients, compared to CS III.The patients treated with observation were found to have a shorter PFS compared to patients who underwent RPLND.Patients with viable tumors after RPLND had shorter OS compared to patients with teratoma and fibrosis.Conclusions: RPLND continues to be the treatment of choice to patients with RM after CT and NSM.